首页> 外文期刊>BMC Infectious Diseases >Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
【24h】

Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure

机译:肺结核治疗后痰中的可行的分枝杆菌结核病

获取原文
           

摘要

BACKGROUND:Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis in the sputum is a major source of transmission. In resource limited TB endemic settings, cure is declared through sputum smear examination for acid fast bacilli without performing culture. This may lead to erroneous treatment outcomes as viable bacteria may be missed due to the low sensitivity of direct smear method. The aim of this study was to investigate if sterilizing cure is achieved among the new pulmonary TB cases declared cured by sputum smear conversion and to evaluate the impact of addition of ethambutol in the continuation phase in achieving it.METHODS:New sputum smear-positive pulmonary TB patients registered at a tertiary care hospital in Pakistan from November 2013 to March 2014 were followed under standard Directly Observed Treatment Short Course strategy for 6 months. Half of these patients received ethambutol in addition to isoniazid and rifampicin in the continuation phase. Sputum specimens were examined on microscopy at 2?months and at the end of treatment. Sputa of patients with negative direct smear examination at the end of treatment were cultured.RESULTS:Among 5746?TB suspects, 1595 were new sputum smear positive pulmonary TB cases, and 533 were registered at our hospital. Among these, 504 converted sputum negative at 2?months and 348 converted at the end of 6 months of treatment and were declared cured. Sputa of 204/348 patients were cultured, and 12/204 (6%) were culture-positive. Culture positivity at 6?months was not associated with bacterial load, smoking, diabetes, presence of cavities, history of contact with TB patients, age, sex, socioeconomic status, or addition of ethambutol in the continuation phase.CONCLUSION:Viable cultivable bacilli were detected in 6% of cured patients, which would have significant impact on the control of TB. This highlights the need for an inexpensive and accurate surrogate marker for culture as it is not feasible to perform culture in routine for monitoring treatment response in the low-resource settings. The treatment outcome did not improve by addition of ethambutol emphasizing the need to find the optimal duration of treatment for individual or carefully selected groups of patients.
机译:背景:痰中具有可检测的分枝杆菌的肺结核(TB)是痰中的主要传播源。在资源有限的TB流行设置中,通过酸快速杆菌的痰涂片检查宣布治愈,而无需进行培养。这可能导致错误的治疗结果,因为由于直接涂片方法的敏感性低,可能会错过活细菌。本研究的目的是调查在通过痰涂片转换的新肺结核病例中达到灭菌治疗,并评估了在实现其延期阶段中加入乙胺醇的影响。方法:新痰涂层阳性肺部2013年11月至2014年11月在巴基斯坦在巴基斯坦的第三级护理医院注册的TB患者在标准下,直接观察到治疗短期课程策略6个月。除了在持续阶段的异烟肼和利福平外,这些患者中的一半是乙胺丁醇。在2个月和治疗结束时,在显微镜下检查痰样品。培养治疗结束时负面直接涂抹检查的患者的Sputa。结果:5746?TB嫌疑人,1595年是新的痰涂片阳性肺结核案,我们医​​院注册了533名。其中,504个转化的痰为2?月份和348次在6个月的治疗结束时转换,并宣布治愈。培养了204/348名患者的斯波塔,12/204(6%)是培养阳性的。 6月6日的培养阳性与细菌载荷,吸烟,糖尿病,蛀牙的存在无关,与TB患者的接触史,年龄,性别,社会经济地位,或在持续期中添加乙胺醇。结论:可行的可种植肉芽肿在6%的治愈患者中检测到,对TB的控制产生重大影响。这突出了对文化的廉价和准确的替代标记的需要,因为在低资源环境中监测治疗响应的常规中不可行。通过添加乙胺醇并强调需要找到对个体或仔细选定的患者组的最佳治疗持续时间的需要改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号